The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease
Open accessAbstract
Parkinson’s disease (PD) is a neurodegenerative disorder, caused by, so far, unknown pathogenetic mechanisms. There is no doubt that pro-inflammatory immune-mediated mechanisms are pivotal to the pathogenicity and progression of the disease. In this review, we highlight the binary role of microglia activation in the pathophysiology of the disorder, both neuroprotective and neuromodulatory. We present how the expression of several cytokines implicated in dopaminergic neurons (DA) degeneration could be used as biomarkers for PD. Viral infections have been studied and correlated to the disease progression, usually operating as trigger factors for the inflammatory process. The gut–brain axis and the possible contribution of the peripheral bowel inflammation to neuronal death, mainly dopaminergic neurons, seems to be a main contributor of brain neuroinflammation. The role of the immune system has also been analyzed implicating a-synuclein in the activation of innate and adaptive immunity. We also discuss therapeutic approaches concerning PD and neuroinflammation, which have been studied in experimental and in vitro models and data stemming from epidemiological studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Teema, A. M., Zaitone, S. A., & Moustafa, Y. M. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.034 · Cited by 66
RetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 2×
“The presence of Lewy body formations in the gut has led the scientific community to further investigate this possible gut–brain connection in PD patients [11].”
BackgroundMutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Microglia Function in the Central Nervous System During Health and Neurodegeneration
Colonna, M., & Butovsky, O. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052358 · Cited by 2,894
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472
Gut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
Microglia as a source and target of cytokines
Hanisch, U. (2002) · Glia · doi:10.1002/glia.10161 · Cited by 1,645 · cited 1×
“Other common stimuli for microglia activation, both in vitro and in vivo, are interferon (IFN)-γ, β-amyloid (Aβ), lipopolysaccharide (LPS), and α-synuclein [22].”
BackgroundAssociation between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene
Lücking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B. S., Meco, G., Denèfle, P., Wood, N. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422103 · Cited by 1,433
Mazzulli, J. R., Xu, Y.-H., Sun, Y., Knight, A. L., McLean, P. J., Caldwell, G. A., Sidransky, E., Grabowski, G. A., & Krainc, D. (2011) · Cell · doi:10.1016/j.cell.2011.06.001 · Cited by 1,341
Colonic bacterial composition in Parkinson's disease
Keshavarzian, A., Green, S. J., Engen, P. A., Voigt, R. M., Naqib, A., Forsyth, C. B., Mutlu, E., & Shannon, K. M. (2015) · Movement Disorders · doi:10.1002/mds.26307 · Cited by 1,281 · cited 2×
“These studies showed that overexpression of human a-synuclein in mice leads to the development of parkinsonian symptoms along with aggregations of a-synuclein in the gut and brain [66].”
BackgroundMOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE
Moore, D. J., West, A. B., Dawson, V. L., & Dawson, T. M. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135718 · Cited by 1,280
The blood-brain barrier in systemic inflammation
Varatharaj, A., & Galea, I. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.03.010 · Cited by 1,172 · cited 2×
“The increased level of the peripheral cytokines that act on the endothelial cells of the blood brain barrier (BBB) cause an increase in vascular permeability [20].”
BackgroundBrochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172
T cells from patients with Parkinson’s disease recognize α-synuclein peptides
Sulzer, D., Alcalay, R. N., Garretti, F., Cote, L., Kanter, E., Agin-Liebes, J., Liong, C., McMurtrey, C., Hildebrand, W. H., Mao, X., et al. (2017) · Nature · doi:10.1038/nature22815 · Cited by 866 · cited 1×
“More specifically, experimental data from a mouse model suggest a PD-associated shift to a Tc1/Th1- type immune response, based on the increased ratio of CD8+ Tc to CD4+ Th and the increased ratio of IFN-γ producing T cells to IL-4 producing T cells [60].”
BackgroundVagotomy and subsequent risk of Parkinson's disease
Svensson, E., Horváth‐Puhó, E., Thomsen, R. W., Djurhuus, J. C., Pedersen, L., Borghammer, P., & Sørensen, H. T. (2015) · Annals of Neurology · doi:10.1002/ana.24448 · Cited by 806
The cytokine storm of severe influenza and development of immunomodulatory therapy
Liu, Q., Zhou, Y.-H., & Yang, Z.-Q. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.74 · Cited by 716
Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
Hruska, K. S., LaMarca, M. E., Scott, C. R., & Sidransky, E. (2008) · Human Mutation · doi:10.1002/humu.20676 · Cited by 678
Epidemiology of parkinson’s disease
Tanner, C. M., & Goldman, S. M. (1996) · Neurologic Clinics · doi:10.1016/s0733-8619(05)70259-0 · Cited by 640 · cited 1×
“The increased incidence of the disease is related to the aging of the population [2].”
BackgroundColonic inflammation in Parkinson's disease
Devos, D., Lebouvier, T., Lardeux, B., Biraud, M., Rouaud, T., Pouclet, H., Coron, E., Bruley des Varannes, S., Naveilhan, P., Nguyen, J.-M., et al. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.09.007 · Cited by 627 · cited 1×
“Both studies found a potential decreased risk for PD after truncal vagotomy compared to patients who underwent superselective vagotomy and the general population [69,70].”
ResultMollenhauer, B., Locascio, J. J., Schulz-Schaeffer, W., Sixel-Döring, F., Trenkwalder, C., & Schlossmacher, M. G. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70014-x · Cited by 622
Microglia clear neuron-released α-synuclein via selective autophagy and prevent neurodegeneration
Choi, I., Zhang, Y., Seegobin, S. P., Pruvost, M., Wang, Q., Purtell, K., Zhang, B., & Yue, Z. (2020) · Nature Communications · doi:10.1038/s41467-020-15119-w · Cited by 608 · cited 1×
“On the other hand, the neuroprotective role for microglia was confirmed in a recent study on mice where the microglia’s major role in the clearance of neuron-released α-synuclein was identified [30].”
BackgroundAlpha‐synuclein RT ‐Qu IC in the CSF of patients with alpha‐synucleinopathies
Fairfoul, G., McGuire, L. I., Pal, S., Ironside, J. W., Neumann, J., Christie, S., Joachim, C., Esiri, M., Evetts, S. G., Rolinski, M., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.338 · Cited by 608 · cited 1×
“Unfortunately, this method had low specificity, but had high positive predictive value that could be used for stratification of patients in future clinical trials [56].”
MethodPINK1 Protects against Oxidative Stress by Phosphorylating Mitochondrial Chaperone TRAP1
Pridgeon, J. W., Olzmann, J. A., Chin, L.-S., & Li, L. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050172 · Cited by 596 · cited 1×
“Missense mutations in the PTEN-induced putative kinase1 (PINK1) gene are the cause for an early-onset form of Parkinson’s that is recessively inherited [82].”
BackgroundNuytemans, K., Theuns, J., Cruts, M., & Van Broeckhoven, C. (2010) · Human Mutation · doi:10.1002/humu.21277 · Cited by 563
Classic and New Animal Models of Parkinson's Disease
Blesa, J., Phani, S., Jackson-Lewis, V., & Przedborski, S. (2012) · Journal of Biomedicine and Biotechnology · doi:10.1155/2012/845618 · Cited by 505
Elyaman, W., Bradshaw, E. M., Uyttenhove, C., Dardalhon, V., Awasthi, A., Imitola, J., Bettelli, E., Oukka, M., van Snick, J., Renauld, J.-C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0812530106 · Cited by 498
Parkinson’s disease: animal models and dopaminergic cell vulnerability
Blesa, J., & Przedborski, S. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00155 · Cited by 480
Vagotomy and Parkinson disease: A Swedish register–based matched-cohort study
Liu, B., Fang, F., Pedersen, N. L., Tillander, A., Ludvigsson, J. F., Ekbom, A., Svenningsson, P., Chen, H., & Wirdefeldt, K. (2017) · Neurology · doi:10.1212/wnl.0000000000003961 · Cited by 447
The Role of the Vagus Nerve in Cytokine‐to‐Brain Communication
MAIER, S. F., GOEHLER, L. E., FLESHNER, M., & WATKINS, L. R. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb09569.x · Cited by 436
LRRK2 Is Involved in the IFN-γ Response and Host Response to Pathogens
Gardet, A., Benita, Y., Li, C., Sands, B. E., Ballester, I., Stevens, C., Korzenik, J. R., Rioux, J. D., Daly, M. J., Xavier, R. J., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000548 · Cited by 415
Gut-seeded α-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice
Challis, C., Hori, A., Sampson, T. R., Yoo, B. B., Challis, R. C., Hamilton, A. M., Mazmanian, S. K., Volpicelli-Daley, L. A., & Gradinaru, V. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0589-7 · Cited by 405
Kirik, D., Annett, L. E., Burger, C., Muzyczka, N., Mandel, R. J., & Björklund, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536383100 · Cited by 403
α-Synuclein-specific T cell reactivity is associated with preclinical and early Parkinson’s disease
Lindestam Arlehamn, C. S., Dhanwani, R., Pham, J., Kuan, R., Frazier, A., Rezende Dutra, J., Phillips, E., Mallal, S., Roederer, M., Marder, K. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15626-w · Cited by 386 · cited 1×
“This process highlights the implication of the innate immune system to the disease course, and mostly the fact that α-synuclein fibrils are potentially involved in the early stages of PD, and therefore they are promising candidate biomarkers for the preclinical PD [53,54].”
BackgroundPeter, I., Dubinsky, M., Bressman, S., Park, A., Lu, C., Chen, N., & Wang, A. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0605 · Cited by 386
Hui, K. Y., Fernandez-Hernandez, H., Hu, J., Schaffner, A., Pankratz, N., Hsu, N.-Y., Chuang, L.-S., Carmi, S., Villaverde, N., Li, X., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aai7795 · Cited by 384
McCoy, M. K., Martinez, T. N., Ruhn, K. A., Szymkowski, D. E., Smith, C. G., Botterman, B. R., Tansey, K. E., & Tansey, M. G. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1504-06.2006 · Cited by 354
Genome-wide pleiotropy between Parkinson disease and autoimmune diseases
Witoelar, A., Jansen, I. E., Wang, Y., Desikan, R. S., Gibbs, J. R., Blauwendraat, C., Thompson, W. K., Hernandez, D. G., Djurovic, S., Schork, A. J., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0469 · Cited by 352
A possible role for humoral immunity in the pathogenesis of Parkinson's disease
Orr, C. F., Rowe, D. B., Mizuno, Y., Mori, H., & Halliday, G. M. (2005) · Brain · doi:10.1093/brain/awh625 · Cited by 350
Alterations of T-lymphocyte populations in Parkinson disease
Baba, Y., Kuroiwa, A., Uitti, R. J., Wszolek, Z. K., & Yamada, T. (2005) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2005.07.005 · Cited by 336
Role of cytokines in inflammatory process in Parkinson’s disease
Sawada, M., Imamura, K., & Nagatsu, T. (2006) · Parkinson’s Disease and Related Disorders · doi:10.1007/978-3-211-45295-0_57 · Cited by 331 · cited 1×
“Although neurons usually lack MHC expression, SN and Locus Coeruleus (LC) neurons have been found expressing MHC after IFNγ stimulation [25].”
BackgroundTayebi, N. (2003) · Molecular Genetics and Metabolism · doi:10.1016/s1096-7192(03)00071-4 · Cited by 327
Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease
Benner, E. J., Mosley, R. L., Destache, C. J., Lewis, T. B., Jackson-Lewis, V., Gorantla, S., Nemachek, C., Green, S. R., Przedborski, S., & Gendelman, H. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400569101 · Cited by 321
Alpha‐Synuclein as a Biomarker for Parkinson's Disease
Atik, A., Stewart, T., & Zhang, J. (2016) · Brain Pathology · doi:10.1111/bpa.12370 · Cited by 311
Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease
Collins, L. M., Toulouse, A., Connor, T. J., & Nolan, Y. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.028 · Cited by 306
Liu, B., Gao, H.-M., & Hong, J.-S. (2003) · Environmental Health Perspectives · doi:10.1289/ehp.6361 · Cited by 285
The Metabolism of Glucocerebrosides
Brady, R. O., Kanfer, J., & Shapiro, D. (1965) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)97611-8 · Cited by 278
Kustrimovic, N., Comi, C., Magistrelli, L., Rasini, E., Legnaro, M., Bombelli, R., Aleksic, I., Blandini, F., Minafra, B., Riboldazzi, G., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1248-8 · Cited by 278
Cerebrospinal fluid lysosomal enzymes and alpha‐synuclein in Parkinson's disease
Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Qureshi, M. M., Dardis, A., Deganuto, M., De Carlo, C., Castrioto, A., et al. (2014) · Movement Disorders · doi:10.1002/mds.25772 · Cited by 266
Neurodegeneration and Inflammation in Parkinson's disease
Phani, S., Loike, J. D., & Przedborski, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70064-5 · Cited by 263 · cited 1×
“The progressive degeneration of DA neurons was identified in substantia nigra pars compacta (SNpc), along with the inclusions of aggregated misfolded a-synuclein, also known as Lewy bodies [8,9].”
BackgroundParkin Deficiency Increases Vulnerability to Inflammation-Related Nigral Degeneration
Frank-Cannon, T. C., Tran, T., Ruhn, K. A., Martinez, T. N., Hong, J., Marvin, M., Hartley, M., Treviño, I., O'Brien, D. E., Casey, B., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3001-08.2008 · Cited by 261
Cellular and Molecular Mediators of Neuroinflammation in the Pathogenesis of Parkinson’s Disease
More, S. V., Kumar, H., Kim, I. S., Song, S.-Y., & Choi, D.-K. (2013) · Mediators of Inflammation · doi:10.1155/2013/952375 · Cited by 258
Hensley, K. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1414 · Cited by 248
Ubiquitin–proteasome system and Parkinson's diseases
Betarbet, R., Sherer, T. B., & Greenamyre, J. T. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2004.08.021 · Cited by 245
Mandler, M., Valera, E., Rockenstein, E., Weninger, H., Patrick, C., Adame, A., Santic, R., Meindl, S., Vigl, B., Smrzka, O., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1256-4 · Cited by 229
α-Synuclein activates stress signaling protein kinases in THP-1 cells and microglia
Klegeris, A., Pelech, S., Giasson, B. I., Maguire, J., Zhang, H., McGeer, E. G., & McGeer, P. L. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.11.013 · Cited by 227 · cited 1×
“Activated microglia proceed to the phagocytosis of a-synuclein aggregates, inducing an immune response, which ultimately leads to neurodegeneration [52].”
BackgroundEnvironmental Exposures and Parkinson’s Disease
Nandipati, S., & Litvan, I. (2016) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph13090881 · Cited by 218
Tomás-Camardiel, M., Rite, I., Herrera, A. J., de Pablos, R. M., Cano, J., Machado, A., & Venero, J. L. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.01.010 · Cited by 203
Impaired Inflammatory Responses in Murine Lrrk2-Knockdown Brain Microglia
Kim, B., Yang, M.-S., Choi, D., Kim, J.-H., Kim, H.-S., Seol, W., Choi, S., Jou, I., Kim, E.-Y., & Joe, E.-H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034693 · Cited by 203
Stool Immune Profiles Evince Gastrointestinal Inflammation in Parkinson's Disease
Houser, M. C., Chang, J., Factor, S. A., Molho, E. S., Zabetian, C. P., Hill‐Burns, E. M., Payami, H., Hertzberg, V. S., & Tansey, M. G. (2018) · Movement Disorders · doi:10.1002/mds.27326 · Cited by 199
Ferger, B., Leng, A., Mura, A., Hengerer, B., & Feldon, J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02399.x · Cited by 186
Regulation of astrocyte inflammatory responses by the Parkinson's disease‐associated gene DJ–1
Waak, J., Weber, S. S., Waldenmaier, A., Görner, K., Alunni‐Fabbroni, M., Schell, H., Vogt‐Weisenhorn, D., Pham, T., Reumers, V., Baekelandt, V., et al. (2009) · The FASEB Journal · doi:10.1096/fj.08-125153 · Cited by 186
Recent Advances in Biomarkers for Parkinson’s Disease
He, R., Yan, X., Guo, J., Xu, Q., Tang, B., & Sun, Q. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00305 · Cited by 175
Karpenko, M. N., Vasilishina, A. A., Gromova, E. A., Muruzheva, Z. M., & Bernadotte, A. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.02.011 · Cited by 172
The association between infectious burden and Parkinson's disease: A case-control study
Bu, X.-L., Wang, X., Xiang, Y., Shen, L.-L., Wang, Q.-H., Liu, Y.-H., Jiao, S.-S., Wang, Y.-R., Cao, H.-Y., Yi, X., et al. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.05.015 · Cited by 169
The role of inflammation in sporadic and familial Parkinson’s disease
Deleidi, M., & Gasser, T. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1352-y · Cited by 167
Ezcurra, A. L. D. L., Chertoff, M., Ferrari, C. C., Graciarena, M., & Pitossi, F. J. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.018 · Cited by 164
Snaring the Function of α-Synuclein
Bonini, N. M., & Giasson, B. I. (2005) · Cell · doi:10.1016/j.cell.2005.10.017 · Cited by 162
Starke Belege: Parkinson könnte im Verdauungstrakt beginnen
(2017) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-0043-113319 · Cited by 161
Clinical and Pathological Features of Parkinson’s Disease
Schneider, S. A., & Obeso, J. A. (2014) · Current topics in behavioral neurosciences · doi:10.1007/7854_2014_317 · Cited by 147
Herpesviruses in brains in Alzheimer's and Parkinson's diseases
Hemling, N., Röyttä, M., Rinne, J. O., Pöllänen, P., Broberg, E., Tapio, V., Vahlberg, T. J., & Hukkanen, V. (2003) · Annals of Neurology · doi:10.1002/ana.10662 · Cited by 143
Picca, A., Guerra, F., Calvani, R., Marini, F., Biancolillo, A., Landi, G., Beli, R., Landi, F., Bernabei, R., Bentivoglio, A. R., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020504 · Cited by 140
Ibuprofen protects dopaminergic neurons against glutamate toxicity in vitro
Casper, D., Yaparpalvi, U., Rempel, N., & Werner, P. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01294-5 · Cited by 138
Sadasivan, S., Zanin, M., O’Brien, K., Schultz‐Cherry, S., & Smeyne, R. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0124047 · Cited by 138
Imamura, K., Hishikawa, N., Ono, K., Suzuki, H., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2004) · Acta Neuropathologica · doi:10.1007/s00401-004-0919-y · Cited by 137
Rees, K., Stowe, R. L., Patel, S., Ives, N. J., Breen, K. C., Clarke, C. E., & Ben‐Shlomo, Y. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008454.pub2 · Cited by 136
Cebrián, C., Loike, J. D., & Sulzer, D. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00114 · Cited by 134
Niwa, F., Kuriyama, N., Nakagawa, M., & Imanishi, J. (2011) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2011.00740.x · Cited by 130
CCL28 chemokine: An anchoring point bridging innate and adaptive immunity
Mohan, T., Deng, L., & Wang, B. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.08.012 · Cited by 130
Rees, K., Stowe, R. L., Patel, S., Ives, N. J., Breen, K. C., Clarke, C. E., & Ben‐Shlomo, Y. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008454 · Cited by 130
Sánchez-Guajardo, V., Annibali, A., Jensen, P. H., & Romero‐Ramos, M. (2013) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31829768d2 · Cited by 117
The correlation of lymphocyte subsets, natural killer cell, and Parkinson’s disease: a meta-analysis
Jiang, S., Gao, H., Luo, Q., Wang, P., & Yang, X. (2017) · Neurological Sciences · doi:10.1007/s10072-017-2988-4 · Cited by 113
Altered Gut Microbiome and Intestinal Pathology in Parkinson’s Disease
Chiang, H., & Lin, C. (2019) · Journal of Movement Disorders · doi:10.14802/jmd.18067 · Cited by 113
García-Domínguez, I., Veselá, K., García-Revilla, J., Carrillo-Jiménez, A., Roca-Ceballos, M. A., Santiago, M., de Pablos, R. M., & Venero, J. L. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00398 · Cited by 111
Translated mutation in the Nurr1 gene as a cause for Parkinson's disease
Grimes, D. A., Han, F., Panisset, M., Racacho, L., Xiao, F., Zou, R., Westaff, K., & Bulman, D. E. (2006) · Movement Disorders · doi:10.1002/mds.20820 · Cited by 108
Restelli, L. M., Oettinghaus, B., Halliday, M., Ağca, C., Licci, M., Sironi, L., Savoia, C., Hench, J., Tolnay, M., Neutzner, A., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.07.023 · Cited by 108
Poly, T. N., Islam, M. M., Yang, H., & Li, Y.-C. J. (2018) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-018-2561-y · Cited by 108
Fibroblast growth factor 21 night watch: advances and uncertainties in the field
Kharitonenkov, A., & DiMarchi, R. D. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12580 · Cited by 105
Th9 cells in the pathogenesis of EAE and multiple sclerosis
Elyaman, W., & Khoury, S. J. (2016) · Seminars in Immunopathology · doi:10.1007/s00281-016-0604-y · Cited by 101
CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders
Mondello, S., Constantinescu, R., Zetterberg, H., Andréasson, U., Holmberg, B., & Jeromin, A. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.01.011 · Cited by 100
Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner
Shutinoski, B., Hakimi, M., Harmsen, I. E., Lunn, M., Rocha, J., Lengacher, N., Zhou, Y. Y., Khan, J., Nguyen, A., Hake-Volling, Q., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aas9292 · Cited by 96 · cited 1×
“Moreover, LRRK2 has been detected in B lymphocytes and macrophages, indicating an active participation in immune response [76].”
BackgroundCorrelation between Serum RANTES Levels and the Severity of Parkinson’s Disease
Tang, P., Li, C., Li, X., Liu, Y., Liu, P., Hou, C., & Li, R. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/208408 · Cited by 96
Jing, H., Wang, S., Wang, M., Fu, W., Zhang, C., & Xu, D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0169560 · Cited by 96
Inflammation biomarker discovery in Parkinson’s disease and atypical parkinsonisms
Santaella, A., Kuiperij, H. B., van Rumund, A., Esselink, R. A. J., van Gool, A. J., Bloem, B. R., & Verbeek, M. M. (2020) · BMC Neurology · doi:10.1186/s12883-020-1608-8 · Cited by 91
LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson's disease
Lee, H., James, W., & Cowley, S. A. (2017) · Biochemical Society Transactions · doi:10.1042/bst20160262 · Cited by 88
Caggiu, E., Paulus, K. S., Arru, G., Piredda, R., Sechi, G., & Sechi, L. A. (2016) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2016.01.007 · Cited by 80
PINK1 Deficiency Enhances Inflammatory Cytokine Release from Acutely Prepared Brain Slices
Kim, J., Byun, J.-W., Choi, I., Kim, B., Jeong, H., Jou, I., & Joe, E.-H. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.1.38 · Cited by 78
Immunotherapy in Parkinson’s disease: Current status and future directions
Chatterjee, D., & Kordower, J. H. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104587 · Cited by 78
Cerami, C., Iaccarino, L., & Perani, D. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18050993 · Cited by 75
Positron emission tomography neuroimaging in Parkinson's disease.
Loane, C., & Politis, M. (2011) · PubMed · Cited by 75
The immunogenetics of neurological disease
Misra, M. K., Damotte, V., & Hollenbach, J. A. (2018) · Immunology · doi:10.1111/imm.12869 · Cited by 74
Gaucher disease and parkinsonism
Sidransky, E. (2005) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2004.11.007 · Cited by 72
Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation
Cunningham, O., Campion, S., Perry, V. H., Murray, C., Sidénius, N., Docagne, F., & Cunningham, C. M. (2009) · Glia · doi:10.1002/glia.20892 · Cited by 72
Hypothesis: A role for EBV-induced molecular mimicry in Parkinson's disease
Woulfe, J., Gray, M. T., Gray, D. A., Muñoz, D. G., & Middeldorp, J. M. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.02.031 · Cited by 68
Pineda, D., Ampurdanés, C., Medina, M. G., Serratosa, J., Tusell, J. M., Saura, J., Planas, A. M., & Navarro, P. (2011) · Glia · doi:10.1002/glia.22284 · Cited by 64
Sadasivan, S., Sharp, B., Schultz‐Cherry, S., & Smeyne, R. J. (2017) · npj Parkinson s Disease · doi:10.1038/s41531-017-0019-z · Cited by 63
Gur‐Wahnon, D., Mizrachi, T., Maaravi-Pinto, F.-Y., Lourbopoulos, A., Grigoriadis, N., Higazi, A. A., & Brenner, T. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-124 · Cited by 58
Li, X., Koudstaal, W., Fletcher, L., Costa, M., van Winsen, M., Siregar, B., Inganäs, H., Kim, J., Keogh, E. A., Macedo, J., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-01974-5 · Cited by 58
Non-Steroidal Anti-Inflammatory Drug Use and the Risk of Parkinson’s Disease
Manthripragada, A. D., Schernhammer, E. S., Qiu, J., Friis, S., Wermuth, L., Olsen, J. H., & Ritz, B. R. (2011) · Neuroepidemiology · doi:10.1159/000325653 · Cited by 57
Boyko, A., Troyanova, N. I., Kovalenko, E. I., & Sapozhnikov, A. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18122633 · Cited by 57
The role of LRRK2 in inflammatory bowel disease
Liu, Z., & Lenardo, M. J. (2012) · Cell Research · doi:10.1038/cr.2012.42 · Cited by 54
Homologous HSV1 and alpha-synuclein peptides stimulate a T cell response in Parkinson's disease
Caggiu, E., Paulus, K. S., Galleri, G., Arru, G., Manetti, R., Sechi, G., & Sechi, L. A. (2017) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2017.06.004 · Cited by 54
A role for viral infections in Parkinson’s etiology?
Olsen, L. K., Dowd, E., & McKernan, D. P. (2018) · Neuronal Signaling · doi:10.1042/ns20170166 · Cited by 53
The S18Y polymorphic variant of UCH-L1 confers an antioxidant function to neuronal cells
Kyratzi, E., Pavlaki, M., & Stefanis, L. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn115 · Cited by 49
Vilensky, J. A., Gilman, S., & McCall, S. A. (2010) · Movement Disorders · doi:10.1002/mds.22908 · Cited by 48
Vaccination strategies in tauopathies and synucleinopathies
Braczynski, A. K., Schulz, J. B., & Bach, J. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14207 · Cited by 45
Encephalitis Lethargica, Us Sequelae and Treatment
von Economo, C. (1931) · Southern Medical Journal · doi:10.1097/00007611-193111000-00029 · Cited by 44
S100B polymorphisms are associated with age of onset of Parkinson’s disease
Fardell, C., Zettergren, A., Ran, C., Belin, A. C., Ekman, A., Sydow, O., Bäckman, L., Holmberg, B., Dizdar, N., Söderkvist, P., et al. (2018) · BMC Medical Genetics · doi:10.1186/s12881-018-0547-3 · Cited by 25
Niaz, A., Karunia, J., Mandwie, M., Keay, K. A., Musumeci, G., Al‐Badri, G., & Castorina, A. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01678-6 · Cited by 18
Lrrk2 alleles modulate inflammation during microbial infection of mice in a sex-dependent manner
Shutinoski, B., Hakimi, M., Harmsen, I., Lunn, M. O., Rocha, J., Lengacher, N. A., Zhou, Y. Y., Khan, J., Nguyen, A., Hake-Volling, Q., et al. (2019) · The Novartis Repository (Novartis) · Cited by 4
Cited by
Calabresi, P., Mechelli, A., Natale, G., Volpicelli-Daley, L., Di Lazzaro, G., & Ghiglieri, V. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-05672-9 · Cited by 817
Adamu, A., Li, S., Gao, F., & Xue, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1347987 · Cited by 564
Microglia Mediated Neuroinflammation in Parkinson’s Disease
Isik, S., Yeman Kiyak, B., Akbayir, R., Seyhali, R., & Arpaci, T. (2023) · Cells · doi:10.3390/cells12071012 · Cited by 379
Pharmacological effects and mechanisms of tannic acid
Jing, W., Xiaolan, C., Yu, C., Feng, Q., & Haifeng, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113561 · Cited by 299
The Emerging Role of Central and Peripheral Immune Systems in Neurodegenerative Diseases
Zang, X., Chen, S., Zhu, J., Ma, J., & Zhai, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.872134 · Cited by 139
Metadata
- Authors
- Marogianni, C., Sokratous, M., Dardiotis, E., Hadjigeorgiou, G. M., Bogdanos, D., & Xiromerisiou, G.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-11-10
- Volume
- 21
- Issue
- 22
- Pages
- 8421
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3098237024
- Cited by
- 366
- References
- 124
- FWCI
- 13.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.